Law360 (April 19, 2018, 7:26 PM EDT) -- The U.S. Drug Enforcement Administration’s plan to examine the extent to which prescription opioids are diverted for illicit purposes when setting limits on manufacturing is a belated but significant step that will compel drugmakers to more rigorously monitor suspicious sales, experts say.
The DEA described its plan on Tuesday in a proposed rule related to limits, or “quotas,” on opioid production. There is currently a nationwide quota that establishes maximum production of various opioids, and there are smaller quotas that establish maximum production by specific drugmakers.
The proposed rule’s most striking provision would ensure that drug diversion is considered when the...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!